Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Cesarean delivery rates are increasing in Turkey and a major component of this increase is cesarean on demand. Although data on the rate of cesarean delivery in Turkey is limited, a national study reported a rate of 23.8%. Infectious morbidity, consisting primarily of endomyometritis and wound infection, remains a leading cause of postoperative complications. Estimates of postcesarean infection rates range from 7% to 20%, depending on demographic and obstetric variables. Infection following cesarean delivery results in not only increased hospital stay but also increases the cost of care. Strategies to minimize postoperative infectious and other morbidities have included modifications of surgical technique, changing of gloves, methods of placental delivery, cervical dilatation during cesarean delivery, and altering the uterine position during repair of the uterine incision. Despite these interventions, endometritis is still major problem after cesarean delivery.

Endometritis appears to result from ascending vaginal flora bacteria, with anaerobes playing an important role. The microbes endogenous to the vagina change throughout the course of pregnancy and parturition. Larsen and Galask noted that anaerobic species located in the vagina increase dramatically by the third postpartum day. In many cases, the surgeon's hand, reaching below the infant's head or presenting part, is in direct contact with the vagina. Vaginal bacterial flora have been cultured from the delivering surgeon's glove in 79% (95% confidence interval \[CI\] 58%, 100%) of cesareans that follow labor. In these cases, vaginal flora are delivered directly to the uterus, abdominal cavity, and the abdominal incision. Vaginal preparation has been shown to decrease the quantitative load of vaginal microorganisms as well as to remove certain species of bacteria.


Options:
A: Arm Label: povidone iodine; Type: OTHER; Interventions: Drug: povidone- iodine solution. | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: povidone- iodine solution.; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): CONTROL
B: Arm Label: Chlorhexidine gluconate vaginal scrub and cloth; Type: EXPERIMENTAL; Interventions: Drug: 2% chlorhexidine gluconate cloth, Drug: 4% Chlorhexidine gluconate vaginal scrub | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2% chlorhexidine gluconate cloth | Intervention Type: DRUG; Name: 2% chlorhexidine gluconate cloth; Assigned to Arm(s): Chlorhexidine gluconate vaginal scrub and cloth, Standard Treatment | Intervention Type: DRUG; Name: 4% Chlorhexidine gluconate vaginal scrub; Assigned to Arm(s): Chlorhexidine gluconate vaginal scrub and cloth
C: Arm Label: Betadine douches; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Betadine douches | Arm Label: Non betadine douches; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Betadine douches; Assigned to Arm(s): Betadine douches
D: Arm Label: Iodine-alcohol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iodine-alcohol | Arm Label: Chlorhexidine-alcohol; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine-alcohol | Intervention Type: DRUG; Name: Iodine-alcohol; Assigned to Arm(s): Iodine-alcohol | Intervention Type: DRUG; Name: Chlorhexidine-alcohol; Assigned to Arm(s): Chlorhexidine-alcohol

Answer: A